Can immunotherapy by gene transfer tip the balance against colorectal cancer?

S. M. Todryk, H. Chong, Richard Geoffrey Vile, H. Pandha, N. R. Lemoine

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Gene therapy, in particular the transfer of genes encoding immunostimulatory molecules (cytokines and costimulatory molecules) as well as selectively cytotoxic enzymes and DNA vaccination, has the potential of enhancing cell mediated immune responses against tumours including those of colorectal origin. Genes can be transferred using viral vectors either to cultured tumour cells in vitro that can be returned to the patient as a 'cancer vaccine', or directly to tumour cells in vivo. Vaccination with DNA constructs expressing specific tumour antigens characteristic of colorectal neoplasia can trigger immune recognition and destruction of tumour cells. The aim is to tip the balance from protumour to antitumour mechanisms by generating a local immune response and systemic antitumour immune memory to destroy metastases. Studies in murine models, combined with human studies, show that such approaches could become an adjunct to current treatments for human colorectal cancer in the near future.

Original languageEnglish (US)
Pages (from-to)445-449
Number of pages5
JournalGut
Volume43
Issue number4
StatePublished - 1998
Externally publishedYes

Fingerprint

Immunotherapy
Colorectal Neoplasms
Genes
Neoplasms
Vaccination
Cultured Tumor Cells
Cancer Vaccines
DNA
Neoplasm Antigens
Genetic Therapy
Cytokines
Neoplasm Metastasis
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Todryk, S. M., Chong, H., Vile, R. G., Pandha, H., & Lemoine, N. R. (1998). Can immunotherapy by gene transfer tip the balance against colorectal cancer? Gut, 43(4), 445-449.

Can immunotherapy by gene transfer tip the balance against colorectal cancer? / Todryk, S. M.; Chong, H.; Vile, Richard Geoffrey; Pandha, H.; Lemoine, N. R.

In: Gut, Vol. 43, No. 4, 1998, p. 445-449.

Research output: Contribution to journalArticle

Todryk, SM, Chong, H, Vile, RG, Pandha, H & Lemoine, NR 1998, 'Can immunotherapy by gene transfer tip the balance against colorectal cancer?', Gut, vol. 43, no. 4, pp. 445-449.
Todryk SM, Chong H, Vile RG, Pandha H, Lemoine NR. Can immunotherapy by gene transfer tip the balance against colorectal cancer? Gut. 1998;43(4):445-449.
Todryk, S. M. ; Chong, H. ; Vile, Richard Geoffrey ; Pandha, H. ; Lemoine, N. R. / Can immunotherapy by gene transfer tip the balance against colorectal cancer?. In: Gut. 1998 ; Vol. 43, No. 4. pp. 445-449.
@article{91aabc1ee4ef4749bf900daa1d547001,
title = "Can immunotherapy by gene transfer tip the balance against colorectal cancer?",
abstract = "Gene therapy, in particular the transfer of genes encoding immunostimulatory molecules (cytokines and costimulatory molecules) as well as selectively cytotoxic enzymes and DNA vaccination, has the potential of enhancing cell mediated immune responses against tumours including those of colorectal origin. Genes can be transferred using viral vectors either to cultured tumour cells in vitro that can be returned to the patient as a 'cancer vaccine', or directly to tumour cells in vivo. Vaccination with DNA constructs expressing specific tumour antigens characteristic of colorectal neoplasia can trigger immune recognition and destruction of tumour cells. The aim is to tip the balance from protumour to antitumour mechanisms by generating a local immune response and systemic antitumour immune memory to destroy metastases. Studies in murine models, combined with human studies, show that such approaches could become an adjunct to current treatments for human colorectal cancer in the near future.",
author = "Todryk, {S. M.} and H. Chong and Vile, {Richard Geoffrey} and H. Pandha and Lemoine, {N. R.}",
year = "1998",
language = "English (US)",
volume = "43",
pages = "445--449",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Can immunotherapy by gene transfer tip the balance against colorectal cancer?

AU - Todryk, S. M.

AU - Chong, H.

AU - Vile, Richard Geoffrey

AU - Pandha, H.

AU - Lemoine, N. R.

PY - 1998

Y1 - 1998

N2 - Gene therapy, in particular the transfer of genes encoding immunostimulatory molecules (cytokines and costimulatory molecules) as well as selectively cytotoxic enzymes and DNA vaccination, has the potential of enhancing cell mediated immune responses against tumours including those of colorectal origin. Genes can be transferred using viral vectors either to cultured tumour cells in vitro that can be returned to the patient as a 'cancer vaccine', or directly to tumour cells in vivo. Vaccination with DNA constructs expressing specific tumour antigens characteristic of colorectal neoplasia can trigger immune recognition and destruction of tumour cells. The aim is to tip the balance from protumour to antitumour mechanisms by generating a local immune response and systemic antitumour immune memory to destroy metastases. Studies in murine models, combined with human studies, show that such approaches could become an adjunct to current treatments for human colorectal cancer in the near future.

AB - Gene therapy, in particular the transfer of genes encoding immunostimulatory molecules (cytokines and costimulatory molecules) as well as selectively cytotoxic enzymes and DNA vaccination, has the potential of enhancing cell mediated immune responses against tumours including those of colorectal origin. Genes can be transferred using viral vectors either to cultured tumour cells in vitro that can be returned to the patient as a 'cancer vaccine', or directly to tumour cells in vivo. Vaccination with DNA constructs expressing specific tumour antigens characteristic of colorectal neoplasia can trigger immune recognition and destruction of tumour cells. The aim is to tip the balance from protumour to antitumour mechanisms by generating a local immune response and systemic antitumour immune memory to destroy metastases. Studies in murine models, combined with human studies, show that such approaches could become an adjunct to current treatments for human colorectal cancer in the near future.

UR - http://www.scopus.com/inward/record.url?scp=0031710994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031710994&partnerID=8YFLogxK

M3 - Article

C2 - 9824562

AN - SCOPUS:0031710994

VL - 43

SP - 445

EP - 449

JO - Gut

JF - Gut

SN - 0017-5749

IS - 4

ER -